Skip to main content
NIH funding notice PAR-18-022

Tobacco Use and HIV in Low and Middle Income Countries (R21 Clinical Trial Optional)

Closed on January 7, 2020.

Posted
November 28, 2017
Close date
January 7, 2020
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $371,862 in first-year total cost, median $185,931.

Most frequent study sections

  1. Special Emphasis Panel[ZRG1 AARR-G (55)]2

Most frequent institutions

  1. BOSTON MEDICAL CENTER1
  2. UNIVERSITY OF ALABAMA AT BIRMINGHAM1
Competing awards under PAR-18-022 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2020Quit For Life (QFL): Smoking Cessation Among Chinese Smokers Living with HIV1R21CA243835-01A1QUINTILIANI, LISA M.BOSTON MEDICAL CENTER, MA$203,767ZRG1
2020Development, Implementation, and Evaluation of a Tobacco Cessation Intervention Tailored to Persons Living with HIV (PLWH) in Brazil: A Feasibility Study1R21DA049557-01A1SCARINCI, ISABEL CUNIVERSITY OF ALABAMA AT BIRMINGHAM, AL$168,095ZRG1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.